One‐week ranitidine bismuth citrate‐based triple therapy for the eradication of <i>Helicobacter pylori</i> in Hong Kong with high prevalence of metronidazole resistance

Abstract

One-week ranitidine bismuth citrate-based triple therapy is significantly better than omeprazole-based triple therapy for the eradication of H. pylori infection, especially in metronidazole-resistant cases. It is an effective regimen for the eradication of H. pylori infection in regions with a high prevalence of metronidazole resistance.